The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment

EBF1-PDGFRB T681I 突变在体外对伊马替尼和达沙替尼具有高度耐药性，并且在治疗前可在临床样本中检测到。